In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (05/2008)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "A Brighter Outlook for Cystic Fibrosis Drugs," features profiles of APT Pharmaceuticals, Aridis, and BioMarck Pharmaceuticals. Plus these Start-Ups Across Health Care: Cannasat, Nanobiotix, Reveal Sciences, and Vertebration.

You may also be interested in...

Vertebration Inc.

People who suffer from lower back pain and opt for spinal surgery may soon have another minimally invasive option for filling the space left following the removal of the damaged or diseased disc. By inserting through a much smaller incision than current devices, the expandable XYcor spinal implant from Vertebration has the potential to spare significant trauma to the soft tissue and bone while it provides mechanical support during the fusion process between the vertebra of the spine.

Aridis Pharmaceuticals LLC

Aridis Pharmaceuticals stabilizes proteins and other complex biological products, which typically must be refrigerated by encasing them in glassy matrices composed of sugar molecules that shield them from environmental stress. Recent studies reveal that high-frequency molecular vibrations that occur in the matrix can be transmitted to these packaged proteins, leading to changes in protein structure and loss of activity or, in the case of a vaccine, making them invisible to the immune system. To counter this, Aridis uses plasticizers to improve the formulations of existing drugs and vaccines.

APT Pharmaceuticals Inc.

When Novartis made clear its intention to acquire Chiron in 2005, a potentially important therapy for lung transplant patients was squeezed out by a numbers game. The drug candidate was an inhaled version of the immunosuppressant cyclosporine, and in a trial it had dramatically improved survival in lung transplant patients. Now, APT Pharmaceuticals takes over where Novartis left off, and it's preparing for a Phase III trial of the lung transplant drug.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts